Safety and tolerability of bosentan in adults with Eisenmenger physiology
- 1 January 2005
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 98 (1) , 147-151
- https://doi.org/10.1016/j.ijcard.2004.08.025
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Neurohormonal Activation and the Chronic Heart Failure Syndrome in Adults With Congenital Heart DiseaseCirculation, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- Prognosis for patients with Eisenmenger syndrome of various aetiologyInternational Journal of Cardiology, 1994
- Circulating endothelin in children with congenital heart disease.Heart, 1993
- Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation.Circulation, 1991
- Surgical management of heart-lung transplantationThe Annals of Thoracic Surgery, 1990
- Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.British Journal of Clinical Pharmacology, 1982
- The Eisenmenger Syndrome: IBMJ, 1958